Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.77 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989041 | 0.88 | PDE10A (0.71) | PDE10ABCL2MCL1BADHSD17B1 | |
| SCHEMBL2459800 | 0.87 | PDE10A (1.00) | PDE10ABCL2MCL1BADHSD17B1 | |
| SCHEMBL14878695 | 0.87 | PDE10A (0.77) | PDE10ABCL2MCL1BADHSD17B1 | |
| SCHEMBL13330630 | 0.85 | PDE10A (0.62) | PDE10ABCL2MCL1BADHSD17B1 | |
| SCHEMBL1303055 | 0.83 | PDE10A (0.71) | PDE10ABCL2MCL1BADHSD17B1 | |
| SCHEMBL2463753 | 0.82 | PDE10A (1.00) | PDE10ABCL2MCL1BAD | |
| SCHEMBL14878647 | 0.80 | PDE10A (0.75) | PDE10ABCL2MCL1BAD | |
| SCHEMBL11989102 | 0.80 | PDE10A (0.61) | PDE10ABCL2MCL1BADHSD17B1 | |
| SCHEMBL2458510 | 0.79 | PDE10A (1.00) | PDE10ABCL2MCL1BAD | |
| SCHEMBL2459577 | 0.79 | PDE10A (1.00) | PDE10ABCL2MCL1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759532-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | PDE10A 3/4885BCL2 3457/4885MCL1 2491/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | PDE10A 3/4885BCL2 3457/4885MCL1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.